Drugs / ION537
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04659096 | Jan 2021 → Oct 2022 | cancer | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ION537 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04659096 ↗ |
| Route | Intravenous | “ION537 will be administered by IV injection.” NCT04659096 ↗ |